How to buy Bioventus Inc stock (Bioventus Inc)

Bioventus Inc is a medical devices business based in the US. Bioventus Inc shares (BVS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $10.52 – a decrease of 4.62% over the previous week. Bioventus Inc employs 1,030 staff and has a trailing 12-month revenue of around $555.1 million.

Our top picks for where to buy Bioventus stock

Buy Bioventus Inc stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Bioventus Inc stock price (NASDAQ: BVS)

Use our graph to track the performance of BVS stocks over time.

Bioventus Inc shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$10.52
52-week range	$3.90 - $14.38
50-day moving average more info button	$12.06
200-day moving average more info button	$8.28
Wall St. target price	$15.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.61

Is it a good time to buy Bioventus Inc stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bioventus Inc price performance over time

Historical closes compared with the close of $10.61 from 2024-12-18

1 week (2024-12-13)	-3.81%
1 month (2024-11-20)	-7.01%
3 months (2024-09-20)	-10.46%
6 months (2024-06-20)	89.46%

1 year (2023-12-20)	103.65%
2 years (2022-12-20)	336.63%
3 years (2021-12-20)	12.85
5 years (2019-12-16)	N/A

Is Bioventus Inc stock undervalued or overvalued?

Valuing Bioventus Inc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bioventus Inc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bioventus Inc's PEG ratio

Bioventus Inc's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1421. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bioventus Inc's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Bioventus Inc's PEG ratio in relation to those of similar companies.

• Bristol-Myers Squibb Company (BMY.US): 1.99
• Johnson-and-Johnson (JNJ.US): 0.88
• Merck-and-Company (MRK.US): 0.07

Bioventus Inc's EBITDA

Bioventus Inc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $50.4 million.

The EBITDA is a measure of a Bioventus Inc's overall financial performance and is widely used to measure a its profitability.

To put Bioventus Inc's EBITDA into context you can compare it against that of similar companies.

• Bristol-Myers Squibb Company (BMY.US): USD$19.2 billion
• Johnson-and-Johnson (JNJ.US): USD$30.1 billion
• Merck-and-Company (MRK.US): USD$22.9 billion

Bioventus Inc financials

Revenue TTM	$555.1 million
Operating margin TTM	4.78%
Gross profit TTM	$302.7 million
Return on assets TTM	2.48%
Return on equity TTM	-24.76%
Profit margin	-7.11%
Book value	$2.28
Market Capitalization more info button	$693.6 million

TTM: trailing 12 months

Bioventus Inc share dividends

We're not expecting Bioventus Inc to pay a dividend over the next 12 months.

You may also wish to consider:

• Bristol-Myers Squibb Company (BMY.US) (4.3% forward annual dividend yield)
• Johnson-and-Johnson (JNJ.US) (3.43% forward annual dividend yield)
• Merck-and-Company (MRK.US) (3.29% forward annual dividend yield)

Bioventus Inc share price volatility

Over the last 12 months, Bioventus Inc's shares have ranged in value from as little as $3.9 up to $14.38. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bioventus Inc's is 0.88. This would suggest that Bioventus Inc's shares are less volatile than average (for this exchange).

To put Bioventus Inc's beta into context you can compare it against those of similar companies.

• Bristol-Myers Squibb Company (BMY.US): 0.441
• Johnson-and-Johnson (JNJ.US): 0.518
• Merck-and-Company (MRK.US): 0.411

Bioventus Inc overview

Bioventus Inc. , a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system.

Frequently asked questions

null
What percentage of Bioventus Inc is owned by insiders or institutions?
Currently 11.477% of Bioventus Inc shares are held by insiders and 69.84% by institutions. How many people work for Bioventus Inc?
Latest data suggests 1,030 work at Bioventus Inc. When does the fiscal year end for Bioventus Inc?
Bioventus Inc's fiscal year ends in December. Where is Bioventus Inc based?
Bioventus Inc's address is: 4721 Emperor Boulevard, Durham, NC, United States, 27703 What is Bioventus Inc's ISIN number?
Bioventus Inc's international securities identification number is: US09075A1088